Satellos Bioscience Inc · TSX:MSCL

Satellos Bioscience — Investor Presentation (October 2025)

19 slides from Satellos Bioscience's investor presentation, October 2025

  1. Slide 1: Regenerating Muscle from Within

    © 2025 Satellos Bioscience R E G E N E R AT I N G M U S C L E F R O M W I T H I N T M

  2. Slide 2: Legal Disclaimers

    © 2025 Satellos Bioscience Legal Disclaimers Certain statements in this presentation are “forward-looking statements” under applicable securities laws. Any The information contained herein is subject to change without statements that express or involve discussions with respect to predictions, expect

  3. Slide 3: Satellos: Who We Are

    © 2025 Satellos Bioscience Satellos: Who We Are  Scientific pioneers with a disruptive therapeutic approach to treating Duchenne muscular dystrophy (DMD)  Novel drug candidate SAT-3247 has been designed to repair and regenerate muscle damaged by disease  Potential to become the 1st truly disease

  4. Slide 4: Rewriting the Duchenne Story

    © 2025 Satellos Bioscience Rewriting the Duchenne Story Infants 2 to 4 years 5 to 9 years 10 to 12 years 13 to 19 years 20 years + Muscle growth occurs Tipping Point Regeneration Fails Muscle loss Muscle has functional capacity > gains Muscle Progressively and Continuously Lost Satellos difference:

  5. Slide 5: Satellos Discovery: Regeneration Fails in DMD

    © 2025 Satellos Bioscience Satellos Discovery: Regeneration Fails in DMD Clinical Confirmation IMBALANCED STEM CELL DIVISION DMD Patients Have an Excess of Stem vs Progenitor Cells Muscle Stem Cells Fail to Divide Efficiently due to Missing a ‘SIGNAL’ Normally Provided by Dystrophin Positive nuclei

  6. Slide 6: Satellos Solution: Restore Regeneration

    © 2025 Satellos Bioscience Satellos Solution: Restore Regeneration Restoring Muscle Re gener ation with SAT-3247 SAT-3247 designed to replace the missing dystrophin ‘SIGNAL’ and reset balanced muscle stem cell divisions by inhibition of AAK1 SAT-3247 designed to safely restore process of regeneratio

  7. Slide 7: SAT-3247 Treatment Shows Muscle Regeneration in Canine Model of DMD

    © 2025 Satellos Bioscience SAT-3247 Treatment Shows Muscle Regeneration in Canine Model of DMD 500um 500um SAT-3247 Study SAT-3247 Study Healthy Age-Matched DMD Animal / Pre-Treatment DMD Animal / Post-Treatment Non-DMD Comparator Bicep Femoris Bicep Femoris Bicep Femoris 60 mg oral dose | 4x/wk | 4

  8. Slide 8: SAT-3247 Treatment Restores Muscle Strength in Canine Model of DMD

    © 2025 Satellos Bioscience SAT-3247 Treatment Restores Muscle Strength in Canine Model of DMD Study Overview SAT-3247 treated vs. historical controls1 Flexion Tetanic Torque  2 DMD dogs: each ~9 mos. of age at start of study  Oral dosing with SAT- N/kg 3247:  1x per day, 60 mg  4 days on, 3 days

  9. Slide 9: Phase 1 Clinical Data

    © 2025 Satellos Bioscience Phase 1 Clinical Data

  10. Slide 10: SAT-3247 Phase 1 First-in-Human Clinical Trial

    © 2025 Satellos Bioscience SAT-3247 Phase 1 First-in-Human Clinical Trial Ph 1a: Healthy Volunteers (n=72) Ph 1b: DMD Adults SAD* Study MAD* Study Food Effect Study 28-day, Open-Label Study  10 - 400 mg  60 - 240 mg  150 mg  60 mg daily dose, weekdays only for 4 weeks  5 cohorts of 8  4 cohort

  11. Slide 11: SAT-3247: Safe and Well-Tolerated in Phase 1 with Desired PK Profile

    © 2025 Satellos Bioscience SAT-3247: Safe and Well-Tolerated in Phase 1 with Desired PK Profile Safety Summary Pharmacokinetic Profiling Key Demographics 11

  12. Slide 12: SAT-3247: 118.6% Increase in Grip Strength in DMD Adults

    © 2025 Satellos Bioscience SAT-3247: 118.6% Increase in Grip Strength in DMD Adults Results exceed natural history comparators  118.6% increase represents a doubling in grip strength across 5 participants  Improvement with SAT-3247 beyond what is reported for natural history  consistently below 1

  13. Slide 13: SAT-3247: 5.8% Increase in FVC in DMD Adults

    © 2025 Satellos Bioscience SAT-3247: 5.8% Increase in FVC in DMD Adults % Predicted Forced Vital Capacity (FVC)  5.8% benefit observed in FVC in Mean change +5.8% n=4 Individual Patients n=4 28 days  Consistent benefit observed across participants (n=4)1  For context: The minimum clinically impor

  14. Slide 14: Grip Strength Improvements Correlate with Cmax and Creatinine Levels

    © 2025 Satellos Bioscience Grip Strength Improvements Correlate with Cmax and Creatinine Levels  Greatest improvements in grip strength occurred in participants with:  highest Cmax on Day 1; and  highest baseline creatinine (surrogate marker for muscle mass) 14

  15. Slide 15: Other Measures in Phase 1b Appeared Stable with No Consistent Trends

    © 2025 Satellos Bioscience Other Measures in Phase 1b Appeared Stable with No Consistent Trends  No consistent trend of benefit across participants with Syde or Maximum Pinch Strength 15

  16. Slide 16: Inside Satellos

    © 2025 Satellos Bioscience Inside Satellos Future plans and the team executing them

  17. Slide 17: SAT-3247: Clinical Trial Program Milestones

    © 2025 Satellos Bioscience SAT-3247: Clinical Trial Program Milestones LT-101 6-month data update: LT-001 Start-up: 3-month data update: Ph 1b Adults • Muscle MRI • Dose returning patients • Grip strength and FVC Up to 20 participants • Grip strength and FVC • Enroll additional patients • Biomarkers

  18. Slide 18: Management Team

    © 2025 Satellos Bioscience Management Team Biotech CPA with 20 years Neuromuscular Neuroscientist with entrepreneur with of biotech finance disease expert with 25+ years of drug 20+ company experience. 10+ years in clinical discovery launches, $500M+ Former CFO of development. experience. in financi

  19. Slide 19: © 2025 Satellos Bioscience

    © 2025 Satellos Bioscience 19

Satellos Bioscience — Investor Presentation (October 2025) on 6ix